LasiodinCAS# 28957-08-6 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 28957-08-6 | SDF | Download SDF |
| PubChem ID | 429192 | Appearance | Cryst. |
| Formula | C22H30O7 | M.Wt | 406.5 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | CC(=O)OC1CCC(C2C13COC(C2O)(C45C3CCC(C4O)C(=C)C5=O)O)(C)C | ||
| Standard InChIKey | DJQLJZNVICMJRV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H30O7/c1-10-12-5-6-13-20-9-28-22(27,21(13,16(10)24)17(12)25)18(26)15(20)19(3,4)8-7-14(20)29-11(2)23/h12-15,17-18,25-27H,1,5-9H2,2-4H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. lasiokaurin has anti-oxidative action. 2. lasiokaurin shows antibacterial activity, esp. against Sarcina lutea. 3. lasiokaurin shows antineoplastic activity against Ehrlich ascites carcinoma. |
| Targets | P450 (e.g. CYP17) | PARP | Caspase | Akt | ERK | JNK | p38MAPK | COX | NF-kB |
Lasiodin Dilution Calculator
Lasiodin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.46 mL | 12.3001 mL | 24.6002 mL | 49.2005 mL | 61.5006 mL |
| 5 mM | 0.492 mL | 2.46 mL | 4.92 mL | 9.8401 mL | 12.3001 mL |
| 10 mM | 0.246 mL | 1.23 mL | 2.46 mL | 4.92 mL | 6.1501 mL |
| 50 mM | 0.0492 mL | 0.246 mL | 0.492 mL | 0.984 mL | 1.23 mL |
| 100 mM | 0.0246 mL | 0.123 mL | 0.246 mL | 0.492 mL | 0.615 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Oridonin
Catalog No.:BCN5953
CAS No.:28957-04-2
- Cassiachromone
Catalog No.:BCN5192
CAS No.:28955-30-8
- Allo-Thr-OH
Catalog No.:BCC3101
CAS No.:28954-12-3
- Canertinib dihydrochloride
Catalog No.:BCC1449
CAS No.:289499-45-2
- Anodendrine
Catalog No.:BCN1956
CAS No.:28942-07-6
- Fmoc-Cl
Catalog No.:BCC2802
CAS No.:28920-43-6
- Triazolam
Catalog No.:BCC5218
CAS No.:28911-01-5
- 3,7,16-Trihydroxystigmast-5-ene
Catalog No.:BCN5191
CAS No.:289056-24-2
- Ergosta-5,24(28)-diene-3,7,16-triol
Catalog No.:BCN5190
CAS No.:289054-34-8
- Z-D-Met-OH
Catalog No.:BCC2758
CAS No.:28862-80-8
- S-(-)-Carbidopa
Catalog No.:BCN8453
CAS No.:28860-95-9
- H-Asp(OBzl)-OBzl.TosOH
Catalog No.:BCC2886
CAS No.:2886-33 -1
- Senicapoc
Catalog No.:BCC1943
CAS No.:289656-45-7
- Boc-HomoArg(NO2)-OH
Catalog No.:BCC2646
CAS No.:28968-64-1
- CB 300919
Catalog No.:BCC1456
CAS No.:289715-28-2
- Pectolinarin
Catalog No.:BCN1217
CAS No.:28978-02-1
- Persicoside
Catalog No.:BCN4780
CAS No.:28978-03-2
- Z-N-Me-Phe-OH
Catalog No.:BCC3349
CAS No.:2899-07-2
- H-Trp-Oet.HCl
Catalog No.:BCC2673
CAS No.:2899-28-7
- H-Tryptophanol
Catalog No.:BCC2701
CAS No.:2899-29-8
- H-Methioninol
Catalog No.:BCC2721
CAS No.:2899-37-8
- 3-(Benzylthio)-Propionic acid
Catalog No.:BCC2839
CAS No.:2899-66-3
- TRAM-34
Catalog No.:BCC1122
CAS No.:289905-88-0
- Boc-Phg-OH
Catalog No.:BCC3311
CAS No.:2900-27-8
Lasiodin inhibits proliferation of human nasopharyngeal carcinoma cells by simultaneous modulation of the Apaf-1/caspase, AKT/MAPK and COX-2/NF-kappaB signaling pathways.[Pubmed:24845412]
PLoS One. 2014 May 20;9(5):e97799.
Rabdosia serra has been widely used for the treatment of the various human diseases. However, the antiproliferative effects and underlying mechanisms of the compounds in this herb remain largely unknown. In this study, an antiproliferative compound against human nasopharyngeal carcinoma (NPC) cells from Rabdosia serra was purified and identified as Lasiodin (a diterpenoid). The treatment with Lasiodin inhibited cell viability and migration. Lasiodin also mediated the cell morphology change and induced apoptosis in NPC cells. The treatment with Lasiodin induced the Apaf-1 expression, triggered the cytochrome-C release, and stimulated the PARP, caspase-3 and caspase-9 cleavages, thereby activating the apoptotic pathways. The treatment with Lasiodin also significantly inhibited the phosphorylations of the AKT, ERK1/2, p38 and JNK proteins. The pretreatment with the AKT or MAPK-selective inhibitors considerably blocked the Lasiodin-mediated inhibition of cell proliferation. Moreover, the treatment with Lasiodin inhibited the COX-2 expression, abrogated NF-kappaB binding to the COX-2 promoter, and promoted the NF-kappaB translocation from cell nuclei to cytosol. The pretreatment with a COX-2-selective inhibitor abrogated the Lasiodin-induced inhibition of cell proliferation. These results indicated that Lasiodin simultaneously activated the Apaf-1/caspase-dependent apoptotic pathways and suppressed the AKT/MAPK and COX-2/NF-kappaB signaling pathways. This study also suggested that Lasiodin could be a promising natural compound for the prevention and treatment of NPC.
